Who is sponsoring NCT02078700?

NCT02078700 is sponsored by Azienda USL Reggio Emilia - IRCCS.

What drugs are being tested in NCT02078700?

Interventions in NCT02078700: The early palliative care programme.

What condition does NCT02078700 study?

NCT02078700 studies Lung Cancer, Mesothelioma, Pancreas Cancer, Gastric Cancer.

Is NCT02078700 still recruiting?

NCT02078700 is currently completed. Last updated 20 June 2025.

Last reviewed 2025-06-20 · How we verify

NCT02078700

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Feasibility of an Early Palliative Care Intervention for Metastatic Cancer Patients. A Phase 2 Study.

Completed Phase 2 Last updated 20 June 2025

What this trial tests

Phase 2 trial testing The early palliative care programme in Lung Cancer in 40 participants. Completed in 1 December 2014.

Timeline

1 July 2013

Primary endpoint
1 April 2014

1 December 2014

Quick facts

Lead sponsor	Azienda USL Reggio Emilia - IRCCS
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	40
Start date	1 July 2013
Primary completion	1 April 2014
Estimated completion	1 December 2014
Sites	1 location across Italy

Drugs / interventions tested

The early palliative care programme

Conditions studied

Lung Cancer — all drugs for Lung Cancer →
Mesothelioma — all drugs for Mesothelioma →
Pancreas Cancer — all drugs for Pancreas Cancer →
Gastric Cancer — all drugs for Gastric Cancer →

Sponsor

Azienda USL Reggio Emilia - IRCCS — full company profile →

Who can join

18 and older, any sex, with Lung Cancer or Mesothelioma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

percentage of cancer patients that accept and attend the early palliative care programme
Time frame: up to 30 days after the diagnosis of cancer
percentage of eligible cancer patients that accept the proposal of the intervention (the early palliative care programme) and that, by 30 days after the diagnosis, effectively start to be followed by the Palliative Care Unit

Sponsor's own description

The objective of this phase 2 study is to evaluate the feasibility of an early palliative care intervention for metastatic cancer patients. Feasibility will be assessed in terms of percentage of patients that accept the proposal of the early palliative care intervention and that effectively start to be followed in the palliative care out-patient clinic. The study will be performed in a consecutive series of newly diagnosed patients affected by lung cancer (NSCLC or SCLC, stage IIIb, IV), mesothelioma (stage II, IV), pancreas (stage IV), stomach (stage IIIb-IV).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Is early integration of palliative care feasible and acceptable for advanced respiratory and gastrointestinal cancer patients? A phase 2 mixed-methods study.
Costantini M, Apolone G, Tanzi S, Falco F, et al · · 2018 · cited 9× · PMID 28952881 · DOI 10.1177/0269216317731571

Verify or expand the search:

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting

Other Azienda USL Reggio Emilia - IRCCS trials

Trials by the same sponsor.

NCT07373626 — Physical Activity Trends in Cancer Survivors Treated at the 'MOvement and REhabilitation' Clinic · recruiting
NCT07000162 — LAttice Radiation Therapy for Large Lesions: Reggio Emilia Single-arm Phase II Trial · Phase 2 · recruiting
NCT06629896 — Contrast Enhancement Mammography vs MRI for the Surveillance of Women at High Risk of Breast Cancer: Con-trust Randomize · NA · recruiting
NCT06749600 — Clinical Management and Outcomes of Primary Ovarian Leiomyosarcoma · recruiting
NCT06624280 — Does Orthopedic Surgery Improve Gait Efficiency in Children With Cerebral Palsy? A Retrospective Study · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02078700 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Azienda USL Reggio Emilia - IRCCS
Last refreshed: 20 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02078700.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing